Which has better valuation & earnings, LNTH or HRMY?

Lantheus has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.34 $233.56M $4.15 24.78 Harmony Biosciences $868.45M 2.20 $158.69M $2.48 13.29

Harmony Biosciences (HRMY) Competitors

$32.96 +0.86 (+2.68%)

Closing price 04:00 PM Eastern

Extended Trading

$32.75 -0.21 (-0.64%)

As of 06:11 PM Eastern

Compare

HRMY vs. PCVX, LNTH, KYMR, SYRE, and PTGX

Should you buy Harmony Biosciences stock or one of its competitors? MarketBeat compares Harmony Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harmony Biosciences include Vaxcyte (PCVX), Lantheus (LNTH), Kymera Therapeutics (KYMR), Spyre Therapeutics (SYRE), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Harmony Biosciences compare to Vaxcyte?

Harmony Biosciences (NASDAQ:HRMY) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.20	$158.69M	$2.48	13.29
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

In the previous week, Vaxcyte had 4 more articles in the media than Harmony Biosciences. MarketBeat recorded 5 mentions for Vaxcyte and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.34 beat Vaxcyte's score of 0.21 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Harmony Biosciences	Positive
Vaxcyte	Neutral

Harmony Biosciences has a net margin of 16.20% compared to Vaxcyte's net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Vaxcyte	N/A	-32.51%	-29.51%

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Harmony Biosciences presently has a consensus target price of $40.89, indicating a potential upside of 24.06%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 76.37%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Harmony Biosciences beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Harmony Biosciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Lantheus currently has a consensus target price of $101.86, indicating a potential downside of 0.94%. Harmony Biosciences has a consensus target price of $40.89, indicating a potential upside of 24.06%. Given Harmony Biosciences' higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

99.1% of Lantheus shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Lantheus had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for Lantheus and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.34 beat Lantheus' score of 0.54 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantheus	Positive
Harmony Biosciences	Positive

Lantheus has a net margin of 18.05% compared to Harmony Biosciences' net margin of 16.20%. Lantheus' return on equity of 29.32% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Harmony Biosciences	16.20%	17.19%	11.99%

Lantheus has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78
Harmony Biosciences	$868.45M	2.20	$158.69M	$2.48	13.29

Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Summary

Lantheus beats Harmony Biosciences on 12 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Kymera Therapeutics?

Harmony Biosciences (NASDAQ:HRMY) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Harmony Biosciences has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

86.2% of Harmony Biosciences shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Kymera Therapeutics had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for Kymera Therapeutics and 1 mentions for Harmony Biosciences. Kymera Therapeutics' average media sentiment score of 1.39 beat Harmony Biosciences' score of 1.34 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Harmony Biosciences	Positive
Kymera Therapeutics	Positive

Harmony Biosciences has a net margin of 16.20% compared to Kymera Therapeutics' net margin of -611.94%. Harmony Biosciences' return on equity of 17.19% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Harmony Biosciences currently has a consensus price target of $40.89, suggesting a potential upside of 24.06%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 58.28%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Harmony Biosciences has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.20	$158.69M	$2.48	13.29
Kymera Therapeutics	$39.21M	156.53	-$311.35M	-$3.57	N/A

Summary

Kymera Therapeutics beats Harmony Biosciences on 9 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Spyre Therapeutics currently has a consensus target price of $91.33, indicating a potential upside of 16.38%. Harmony Biosciences has a consensus target price of $40.89, indicating a potential upside of 24.06%. Given Harmony Biosciences' higher probable upside, analysts clearly believe Harmony Biosciences is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Spyre Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Harmony Biosciences. MarketBeat recorded 6 mentions for Spyre Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.34 beat Spyre Therapeutics' score of 0.07 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyre Therapeutics	Neutral
Harmony Biosciences	Positive

Harmony Biosciences has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,657.53	-$155.20M	-$2.08	N/A
Harmony Biosciences	$868.45M	2.20	$158.69M	$2.48	13.29

Harmony Biosciences has a net margin of 16.20% compared to Spyre Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Harmony Biosciences	16.20%	17.19%	11.99%

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Harmony Biosciences beats Spyre Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	143.64	-$130.15M	-$1.81	N/A
Harmony Biosciences	$868.45M	2.20	$158.69M	$2.48	13.29

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Harmony Biosciences. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.34 beat Protagonist Therapeutics' score of 0.72 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Protagonist Therapeutics	Positive
Harmony Biosciences	Positive

Harmony Biosciences has a net margin of 16.20% compared to Protagonist Therapeutics' net margin of -154.88%. Harmony Biosciences' return on equity of 17.19% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Harmony Biosciences	16.20%	17.19%	11.99%

Protagonist Therapeutics presently has a consensus price target of $115.21, indicating a potential upside of 12.09%. Harmony Biosciences has a consensus price target of $40.89, indicating a potential upside of 24.06%. Given Harmony Biosciences' higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Summary

Harmony Biosciences beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRMY vs. The Competition

Export

Metric	Harmony Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.91B	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	13.29	18.78	23.87	24.36
Price / Sales	2.20	320.80	521.52	117.06
Price / Cash	9.72	110.40	41.27	57.13
Price / Book	2.18	6.80	9.99	6.73
Net Income	$158.69M	$24.09M	$3.56B	$337.03M
7 Day Performance	4.67%	-2.56%	-0.90%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-6.26%	48.90%	28.77%	33.98%

Harmony Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRMY Harmony Biosciences	4.6031 of 5 stars	$32.96 +2.7%	$40.89 +24.1%	-9.2%	$1.91B	$868.45M	13.29	200	Positive News
PCVX Vaxcyte	2.8058 of 5 stars	$47.30 flat	$86.00 +81.8%	+35.4%	$6.83B	N/A	N/A	160	Insider Trade
LNTH Lantheus	2.0809 of 5 stars	$103.00 flat	$99.71 -3.2%	+29.0%	$6.71B	$1.54B	24.82	1,193
KYMR Kymera Therapeutics	2.157 of 5 stars	$78.89 flat	$118.10 +49.7%	+67.9%	$6.49B	$39.21M	N/A	170
SYRE Spyre Therapeutics	1.9131 of 5 stars	$74.05 flat	$90.25 +21.9%	+343.7%	$6.43B	$890K	N/A	73	News Coverage Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRMY) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Competitors

HRMY vs. PCVX, LNTH, KYMR, SYRE, and PTGX

How does Harmony Biosciences compare to Vaxcyte?

Summary

How does Harmony Biosciences compare to Lantheus?

Summary

How does Harmony Biosciences compare to Kymera Therapeutics?

Summary

How does Harmony Biosciences compare to Spyre Therapeutics?

Summary

How does Harmony Biosciences compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Competitors

HRMY vs. PCVX, LNTH, KYMR, SYRE, and PTGX

How does Harmony Biosciences compare to Vaxcyte?

Which has more volatility & risk, HRMY or PCVX?

Which has higher earnings & valuation, HRMY or PCVX?

Does the media refer more to HRMY or PCVX?

Is HRMY or PCVX more profitable?

Do institutionals and insiders believe in HRMY or PCVX?

Do analysts prefer HRMY or PCVX?

Summary

How does Harmony Biosciences compare to Lantheus?

Do analysts recommend LNTH or HRMY?

Do insiders & institutionals have more ownership in LNTH or HRMY?

Does the media favor LNTH or HRMY?

Is LNTH or HRMY more profitable?

Which has better valuation & earnings, LNTH or HRMY?

Which has more risk and volatility, LNTH or HRMY?

Summary

How does Harmony Biosciences compare to Kymera Therapeutics?

Which has more volatility and risk, HRMY or KYMR?

Do insiders & institutionals believe in HRMY or KYMR?

Does the media refer more to HRMY or KYMR?

Is HRMY or KYMR more profitable?

Do analysts rate HRMY or KYMR?

Which has better earnings & valuation, HRMY or KYMR?

Summary

How does Harmony Biosciences compare to Spyre Therapeutics?

Do analysts prefer SYRE or HRMY?

Which has more risk and volatility, SYRE or HRMY?

Does the media prefer SYRE or HRMY?

Which has preferable earnings & valuation, SYRE or HRMY?

Is SYRE or HRMY more profitable?

Do institutionals and insiders believe in SYRE or HRMY?

Summary

How does Harmony Biosciences compare to Protagonist Therapeutics?

Do institutionals & insiders believe in PTGX or HRMY?

Which has more risk & volatility, PTGX or HRMY?

Which has stronger valuation & earnings, PTGX or HRMY?

Does the media prefer PTGX or HRMY?

Is PTGX or HRMY more profitable?

Do analysts prefer PTGX or HRMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools